Medical Pharmacology Question Bank
Chapter 9: Antianginal Drugs — Module 3: Beta-Blockers in Angina — Mechanisms and Clinical Application
Tier: Core Concepts — Foundational Knowledge
1. A patient with stable exertional angina is started on metoprolol succinate. The physician explains that the drug reduces angina by decreasing the heart's demand for oxygen. Which of the following best describes the primary mechanism by which beta-blockers reduce myocardial oxygen demand (MVO₂) in angina?
ANSWER: B
Rationale:
Myocardial oxygen demand (MVO₂) is the heart's requirement for oxygen per unit time and is determined primarily by three factors: heart rate, myocardial contractility (the force of contraction), and wall tension (related to preload and afterload). Beta-blockers occupy beta-1 adrenergic receptors on the cardiac myocyte and sinoatrial node, blocking the effects of circulating catecholamines such as epinephrine and norepinephrine. By blocking beta-1 receptors, beta-blockers reduce both heart rate (negative chronotropy) and the force of each contraction (negative inotropy). A slower heart rate also prolongs diastole, which is when the coronary arteries fill — an additional benefit. The net result is a substantial reduction in MVO₂, meaning the myocardium requires less oxygen per minute, reducing the imbalance between supply and demand that causes anginal symptoms. This mechanism is distinct from increasing oxygen supply; beta-blockers do not directly dilate coronary arteries and may mildly reduce supply by allowing coronary vasoconstriction via unopposed alpha tone, yet the demand reduction is sufficient to produce antianginal benefit in the vast majority of patients. Option A: This describes a mechanism of nitrates and some calcium channel blockers, not beta-blockers. Beta-blockers do not directly dilate coronary arteries; in fact, by blocking beta-2-mediated coronary vasodilation, they may allow a mild increase in coronary vascular tone, though the demand reduction dominates clinically. Option C: This describes the mechanism of alpha-1 adrenergic blockers (e.g., prazosin, doxazosin) and the alpha-1 component of carvedilol. Pure beta-blockers do not block alpha-1 receptors. Option D: This describes the mechanism of calcium channel blockers such as amlodipine, diltiazem, and verapamil. Beta-blockers act on adrenergic receptors, not L-type calcium channels. Option E: Beta-blockers have no direct antiplatelet mechanism. Platelet aggregation inhibition is the mechanism of aspirin and P2Y12 inhibitors (e.g., clopidogrel), not beta-blockers.
2. A cardiology fellow describes metoprolol as a "cardioselective" beta-blocker when discussing its use in a patient with mild chronic obstructive pulmonary disease (COPD). A medical student asks what cardioselective means in practical terms. Which of the following statements best describes the meaning of cardioselectivity in beta-blocker pharmacology?
ANSWER: D
Rationale:
Cardioselectivity refers to a preferential affinity for beta-1 adrenergic receptors over beta-2 adrenergic receptors. Beta-1 receptors predominate in the myocardium and sinoatrial node and mediate increases in heart rate and contractility. Beta-2 receptors are found in bronchial smooth muscle (where their stimulation causes bronchodilation), vascular smooth muscle, and skeletal muscle. Cardioselective agents such as metoprolol, bisoprolol, atenolol, and nebivolol bind beta-1 receptors with greater affinity than beta-2, which means that at low-to-moderate therapeutic doses, bronchospasm and peripheral vasoconstriction are less likely than with non-selective agents such as propranolol or carvedilol. However, this selectivity is relative, not absolute: at high doses, all cardioselective agents will begin to block beta-2 receptors as well. This is why cardioselective agents require caution — not freedom from concern — in patients with reactive airway disease, and why they are used at the lowest effective dose in such patients. Understanding this distinction is clinically important: labeling a drug "cardioselective" does not mean it is risk-free in asthma; it means the risk is reduced and dose-dependent. Option A: This overstates selectivity. No beta-blocker currently available achieves absolute beta-1 selectivity at all doses. The selectivity is always a matter of relative affinity and is dose-dependent. Option B: The mechanism is receptor affinity, not tissue distribution. Cardioselective agents preferentially bind beta-1 receptors regardless of anatomical location; they do not migrate selectively to cardiac tissue. Option C: Alpha-1 receptors are found primarily in vascular smooth muscle, not the heart. Alpha-1 blockade is a property of carvedilol and labetalol — not of cardioselective agents as a class. Option E: This inverts the receptor pharmacology. Positive chronotropy and inotropy in the heart are mediated by beta-1 receptors, not beta-2. Beta-2 receptors in the heart exist but are a minor contributor; their stimulation in bronchial smooth muscle produces bronchodilation, which is preserved by cardioselective blockade.
3. A pharmacology instructor asks students why beta-blockers with intrinsic sympathomimetic activity (ISA) — the property of acting as a partial agonist at the beta-adrenergic receptor while simultaneously blocking the receptor against full agonists — are generally not preferred for the treatment of stable angina. Which of the following best explains this clinical limitation?
ANSWER: A
Rationale:
Intrinsic sympathomimetic activity (ISA) means that a drug acts as a partial agonist at the beta-adrenergic receptor: it occupies the receptor and produces a submaximal stimulatory effect while simultaneously preventing full agonists (epinephrine, norepinephrine) from binding. At rest, when circulating catecholamine levels are low, an ISA agent produces enough partial agonism to maintain heart rate near baseline — in some cases, resting heart rate is not reduced at all. This is the critical clinical problem in angina: the antianginal benefit of beta-blockers depends substantially on reducing resting heart rate and lowering myocardial oxygen demand (MVO₂) throughout the day, not just during exertion. An agent that fails to lower resting heart rate provides incomplete demand reduction. During exertion, when catecholamine levels rise, ISA agents do compete with endogenous agonists and provide some rate control — but the overall antianginal protection across the full 24-hour period is inferior to pure antagonists. Examples of ISA agents include pindolol and acebutolol. These agents may have a role where resting bradycardia is problematic, but they are not preferred for routine angina management. Option B: ISA is a property related to partial agonism, not to receptor selectivity. ISA agents can be cardioselective (acebutolol) or non-selective (pindolol). The beta-2 selectivity profile is independent of ISA status and does not automatically worsen bronchospasm risk. Option C: This is the opposite of the correct pharmacology. ISA agents cause less resting bradycardia than pure antagonists, not more. The concern with ISA agents in angina is insufficient heart rate reduction, not excessive bradycardia. Option D: ISA agents are not uniquely restricted from beta-2 receptor blockade. Selectivity is a separate pharmacological property from ISA. Non-selective ISA agents (pindolol) block beta-2 receptors; the issue is partial agonism, not selective receptor sparing. Option E: The CYP2D6 interaction risk is not a class property of ISA agents. Bisoprolol — cited in the option as a non-ISA comparator — is metabolized by CYP3A4, not CYP2D6, and has fewer CYP2D6-related interactions than metoprolol or nebivolol. The premise of the option is pharmacologically inaccurate.
4. A 44-year-old woman presents with recurrent chest pain that occurs predominantly at rest in the early morning hours, is not consistently triggered by exertion, and is associated with transient ST-segment elevation on electrocardiogram that resolves spontaneously. Coronary angiography reveals no obstructive disease. The cardiologist diagnoses vasospastic angina (also called Prinzmetal or variant angina — a condition in which coronary arteries undergo intermittent intense spasm, temporarily obstructing blood flow). Why are beta-blockers contraindicated in this condition?
ANSWER: C
Rationale:
Coronary vascular tone is regulated by a balance between vasodilatory and vasoconstrictive influences. Beta-2 adrenergic receptors in coronary arterial smooth muscle, when stimulated by circulating catecholamines, produce vasodilation. Alpha-1 adrenergic receptors in the same tissue produce vasoconstriction when stimulated. In normal physiology, this balance is maintained. When a beta-blocker is administered, beta-2 receptor-mediated coronary vasodilation is lost while alpha-1-mediated vasoconstriction remains fully active. This creates a state of "unopposed alpha" activity in the coronary vasculature — the net effect is a shift toward vasoconstriction. In a patient whose coronary arteries are already predisposed to spasm, this pharmacodynamic shift can worsen or precipitate a vasospastic episode. This contraindication applies to all beta-blockers, including cardioselective agents: even though cardioselective agents preferentially block beta-1 at low doses, they still block beta-2 to some degree, and in vasospastic angina even partial removal of coronary beta-2 tone is hazardous. The preferred agents for vasospastic angina are calcium channel blockers (which directly relax vascular smooth muscle) and long-acting nitrates. Option A: Beta-blockers reduce heart rate rather than accelerating it. Negative chronotropy is a primary pharmacological effect of beta-1 blockade; this option describes the opposite of what beta-blockers do. Option B: Beta-blockers have no clinically significant antiplatelet effect. Platelet aggregation inhibition is the mechanism of aspirin and ADP receptor antagonists; attributing this to beta-blockers is pharmacologically incorrect. Option D: Beta-blockers do not stimulate alpha-2 receptors. They are competitive antagonists at beta-adrenergic receptors and have no agonist activity at alpha-adrenergic receptors. The "unopposed alpha" effect operates via alpha-1, not alpha-2, and is a consequence of removing beta-2-mediated vasodilation rather than any direct alpha receptor stimulation. Option E: Beta-blockers do not block L-type calcium channels. This is the mechanism of calcium channel blockers (amlodipine, diltiazem, verapamil). Beta-blockers act solely at beta-adrenergic receptors.
5. A 58-year-old man with stable angina is well-controlled on metoprolol succinate 100 mg daily. His cardiologist adds paroxetine (a selective serotonin reuptake inhibitor used for depression that is also a potent inhibitor of the liver enzyme CYP2D6 — the enzyme responsible for metabolizing metoprolol) for newly diagnosed depression. Two weeks later, the patient returns with symptomatic bradycardia and lightheadedness. Which of the following best explains what happened?
ANSWER: E
Rationale:
Metoprolol undergoes extensive first-pass and systemic hepatic metabolism via CYP2D6 (cytochrome P450 2D6 — a key liver enzyme responsible for metabolizing many cardiovascular and psychiatric drugs). Under normal circumstances in a CYP2D6 extensive metabolizer, this enzyme efficiently breaks down metoprolol, keeping plasma levels within the therapeutic range. Paroxetine is one of the most potent inhibitors of CYP2D6 available and, when added to a stable metoprolol regimen, effectively blocks the primary elimination pathway for metoprolol. The result is a substantial rise in metoprolol plasma concentrations — in some cases to levels three to five times higher than before paroxetine was added — converting the patient pharmacokinetically into a CYP2D6 poor metabolizer status. This produces excessive beta-1 blockade: bradycardia, hypotension, fatigue, and dizziness. The clinical fix is either to switch to bisoprolol (which is metabolized by CYP3A4 and is unaffected by paroxetine) or to reduce the metoprolol dose with close monitoring. Other potent CYP2D6 inhibitors that carry the same interaction risk include fluoxetine, bupropion, and quinidine. Option A: Paroxetine is a serotonin reuptake inhibitor and has no direct agonist activity at beta-adrenergic receptors. It does not directly slow heart rate through any adrenergic mechanism. Option B: Metoprolol is eliminated primarily by hepatic metabolism, not renal tubular secretion. Paroxetine does not interact with renal transporters in a way that raises metoprolol levels; the interaction is entirely hepatic and CYP2D6-mediated. Option C: This option incorrectly states that paroxetine induces CYP2D6. Paroxetine is an inhibitor, not an inducer. Enzyme induction would increase, not decrease, metoprolol metabolism, and would lower — not raise — plasma metoprolol levels. The mechanism described in this option is the opposite of what occurs. Option D: Protein binding displacement is rarely a clinically significant mechanism of drug interaction at therapeutic concentrations, and it does not accurately describe the paroxetine-metoprolol interaction. The relevant mechanism is enzyme inhibition, not protein binding competition.
6. A patient with stable angina and a recent diagnosis of major depression requires both a beta-blocker and an antidepressant. The cardiologist wants to prescribe a beta-blocker that will not be affected by concurrent use of fluoxetine or paroxetine, both of which are potent inhibitors of the liver enzyme CYP2D6. Which beta-blocker is the best choice, and why?
ANSWER: B
Rationale:
Bisoprolol is the correct answer because it is metabolized by CYP3A4 (cytochrome P450 3A4), not CYP2D6 (cytochrome P450 2D6). When fluoxetine or paroxetine inhibit CYP2D6, bisoprolol metabolism is completely unaffected because bisoprolol does not use that enzyme. Bisoprolol also has the highest beta-1 to beta-2 selectivity ratio of any available beta-blocker, making it particularly suitable for patients with comorbidities that make beta-2 blockade undesirable. Approximately 50% of bisoprolol undergoes hepatic metabolism via CYP3A4 and the remaining 50% is eliminated unchanged by the kidneys — a dual pathway that provides pharmacokinetic stability. In contrast, metoprolol, carvedilol, nebivolol, and propranolol all rely substantially on CYP2D6 and would have significantly elevated plasma levels if combined with fluoxetine or paroxetine. When a patient with angina needs a CYP2D6-inhibiting antidepressant, switching to bisoprolol is the pharmacologically rational solution. Option A: The extended-release formulation of metoprolol succinate smooths plasma level fluctuations from absorption variability, but it does not protect against CYP2D6 inhibition. The enzyme still metabolizes the drug; when the enzyme is inhibited, the drug accumulates regardless of the release mechanism. Formulation affects absorption kinetics, not metabolic clearance. Option C: Atenolol is correct that it is renally eliminated and bypasses hepatic CYP metabolism, making it immune to CYP2D6 inhibition. However, the question asks for the best choice given the need for a beta-blocker unaffected by CYP2D6 inhibitors; atenolol requires dose reduction in renal impairment and lacks the outstanding cardioselectivity and evidence base of bisoprolol. In a general clinical scenario, bisoprolol is preferred specifically because of its CYP3A4 metabolism and superior selectivity profile. If the patient had normal renal function and no other preference, atenolol would be pharmacokinetically acceptable but is not the best answer given bisoprolol's advantages. Option D: Lipophilicity determines CNS penetration and tissue distribution but does not protect against hepatic enzyme inhibition. Propranolol is metabolized by CYP2D6 and CYP1A2 and would accumulate significantly when either of these enzymes is inhibited. High lipophilicity does not sequester a drug away from hepatic metabolism. Option E: Carvedilol is metabolized by CYP2D6 and CYP2C9. When CYP2D6 is inhibited, carvedilol plasma levels rise substantially. Its alpha-1 blocking activity does not compensate for accumulation of excessive beta-blocking concentrations — it would add orthostatic hypotension risk on top of bradycardia risk, not protect against the interaction.
7. A 71-year-old man with stable angina and stage 4 chronic kidney disease (CKD — a condition in which the kidneys function at 15–29% of normal capacity, significantly impairing the body's ability to excrete drugs that rely on renal elimination) has been on atenolol 50 mg once daily for years. His nephrologist recommends switching his beta-blocker. Which of the following best explains why atenolol is problematic in advanced CKD, and what represents a more appropriate alternative?
ANSWER: D
Rationale:
Atenolol is one of the most hydrophilic beta-blockers and is unique among commonly used cardioselective agents in being eliminated almost entirely by renal excretion: approximately 85–100% of absorbed atenolol is excreted unchanged in the urine with negligible hepatic metabolism. This makes atenolol highly dependent on glomerular filtration rate (GFR) for clearance. In advanced CKD (stage 4: eGFR 15–29 mL/min/1.73m²), atenolol clearance is severely reduced and the drug accumulates, producing progressively more intense beta-1 blockade — bradycardia, hypotension, AV conduction delay, and fatigue. In patients on hemodialysis, atenolol accumulates substantially and is only partially removed by dialysis, creating unpredictable plasma levels. The preferred alternatives in CKD are bisoprolol (50% hepatic via CYP3A4, 50% renal — moderate CKD tolerated without full dose adjustment) and metoprolol succinate (predominantly hepatic CYP2D6 metabolism; inactive metabolites renally cleared; no dose reduction required in CKD). Both are cardioselective, once-daily, and do not accumulate in the setting of renal impairment. Option A: Atenolol does not undergo meaningful hepatic metabolism via CYP2D6 or any other CYP enzyme. Its elimination is renal, not hepatic. The premise of this option is pharmacologically incorrect — it describes metoprolol, not atenolol. Option B: Beta-blockers can modestly reduce cardiac output, but this does not constitute nephrotoxicity, and atenolol's risks in CKD are due to its accumulation from impaired renal clearance — not from a direct harmful effect on the kidney. Beta-blockers are not nephrotoxic in the conventional sense. Option C: Atenolol undergoes negligible biliary excretion. It is not eliminated via the GI tract. This option describes a pathway that does not apply to atenolol's pharmacokinetics. Option E: This option is false in both parts. Multiple beta-blockers beyond atenolol require consideration in CKD: carvedilol does not require dose adjustment for renal impairment (it is hepatically metabolized) and is appropriate in CKD, while atenolol is the one that is most problematic. Propranolol is also primarily hepatically cleared. The statement that atenolol is the "only" beta-blocker requiring adjustment is incorrect.
8. A physician is reviewing the medication list of a 63-year-old man with stable angina who is already taking metoprolol succinate 100 mg daily. The physician considers adding a calcium channel blocker for additional angina control. The patient's resting heart rate is 62 bpm and his PR interval on ECG is at the upper limit of normal. Which combination represents a contraindicated pairing, and why?
ANSWER: A
Rationale:
The distinction between dihydropyridine (DHP) and non-dihydropyridine (non-DHP) calcium channel blockers is critical for safe prescribing in angina. Verapamil and diltiazem are non-DHP calcium channel blockers: they block L-type calcium channels not only in vascular smooth muscle but also in cardiac myocytes, the sinoatrial node, and the atrioventricular node. This means they slow heart rate (negative chronotropy), depress AV conduction (negative dromotropy), and reduce contractility (negative inotropy) — the same effects as beta-blockers, acting through a different molecular mechanism. When verapamil or diltiazem is combined with any beta-blocker, the cardiac depressant effects are additive and potentially life-threatening: severe symptomatic bradycardia, high-degree AV block, and hemodynamic collapse have all been reported. This combination is contraindicated in routine practice. If a patient on a beta-blocker needs a second antianginal agent that reduces heart rate, the appropriate choice is amlodipine (a DHP agent) — which works on vascular smooth muscle to reduce afterload and has negligible direct cardiac conduction effects — rather than verapamil or diltiazem. Option B: Amlodipine + metoprolol is actually the preferred combination for dual antianginal therapy. Amlodipine can cause mild reflex tachycardia, which the beta-blocker blunts — this is a pharmacodynamic advantage, not a hazard. The option's claim about paradoxical coronary vasoconstriction is not supported by evidence and misrepresents this beneficial pairing. Option C: This option is false. Diltiazem is a non-DHP calcium channel blocker and does affect cardiac conduction and contractility, not just vascular smooth muscle. Diltiazem + metoprolol carries the same risk of additive AV nodal depression as verapamil + metoprolol and is equally contraindicated. Option D: Halving the metoprolol dose does not make the combination of metoprolol + verapamil safe. The pharmacodynamic interaction is an additive depression of the same cardiac targets by two different mechanisms, and reducing one drug's dose does not reliably predict the combined effect. Clinically, this approach has produced severe bradycardia and AV block even at reduced doses and is not recommended. Option E: This overstates the contraindication. Amlodipine and other DHP calcium channel blockers (nifedipine, felodipine) are not contraindicated with beta-blockers; they are commonly and safely co-prescribed. The contraindication applies specifically to non-DHP agents (verapamil and diltiazem) with beta-blockers.
9. A 59-year-old man with stable angina and known coronary artery disease has been taking metoprolol succinate 100 mg daily for three years. He stops the medication abruptly without consulting his physician because he read online that beta-blockers cause fatigue. Four days later he presents to the emergency department with severe chest pain, diaphoresis, and new ST-segment changes. Which of the following best explains the mechanism of this complication?
ANSWER: C
Rationale:
Beta-blocker withdrawal syndrome results from a well-characterized pharmacodynamic adaptation to prolonged receptor blockade. When beta-adrenergic receptors are chronically occupied and blocked, the cell responds by increasing the number of beta-adrenergic receptors on the membrane surface (receptor upregulation) and increasing the sensitivity of those receptors to agonist stimulation. This is a homeostatic response to perceived under-stimulation. When the beta-blocker is abruptly discontinued, this enlarged and supersensitized receptor population is suddenly exposed to normal circulating levels of catecholamines — the same catecholamines that were previously producing only a blunted effect. The result is a dramatically exaggerated adrenergic response: heart rate accelerates far beyond the pre-treatment baseline, blood pressure rises, myocardial oxygen demand surges, platelet aggregability increases, and the threshold for ventricular arrhythmias decreases. In a patient with known coronary artery disease and fixed coronary stenoses, this abrupt increase in oxygen demand produces ischemia that may be more severe than any angina the patient experienced before starting the beta-blocker. Prevention is straightforward: taper the dose over a minimum of one to two weeks, reducing by approximately 50% every three to seven days. This allows receptor populations to return toward baseline gradually before the drug is withdrawn. Option A: Beta-blockers do not have a direct vasodilatory effect on coronary arteries. In fact, beta-2 receptor blockade may slightly increase coronary vascular tone by removing beta-2-mediated vasodilation. The withdrawal mechanism is not loss of vasodilation but rather receptor upregulation and catecholamine supersensitivity. Option B: There is no autoimmune mechanism involved in beta-blocker withdrawal syndrome. The physiology is entirely pharmacodynamic — it is an adrenergic receptor phenomenon, not an immune-mediated process. Option D: Metoprolol does not block alpha-1 receptors. It is a selective beta-1 adrenergic antagonist with no meaningful alpha-1 blocking activity. Alpha-1 receptor blockade is a property of carvedilol and labetalol, not metoprolol or other standard cardioselective agents. Option E: Beta-blockers do not produce opioid-like physical dependence. The withdrawal syndrome is a receptor pharmacodynamics phenomenon (upregulation and supersensitivity) — it is not mediated by CNS sedation, tolerance, or the opioid receptor mechanisms that underlie opioid withdrawal.
10. A 67-year-old man has stable angina and heart failure with reduced ejection fraction (HFrEF — a condition in which the left ventricle pumps less than 40% of its blood volume with each contraction, reducing cardiac output). His echocardiogram shows an ejection fraction of 30%. He is hemodynamically stable and euvolemic on his current heart failure regimen. The cardiologist selects carvedilol for both his angina and heart failure. Which of the following best explains why carvedilol is particularly suited to this combination of diagnoses?
ANSWER: E
Rationale:
Carvedilol is a non-selective beta-adrenergic blocker — it blocks both beta-1 receptors (in the heart, reducing rate and contractility) and beta-2 receptors (in the bronchi and vasculature). In addition, carvedilol blocks alpha-1 adrenergic receptors in vascular smooth muscle, which produces vasodilation and afterload reduction. This alpha-1 blockade lowers systemic vascular resistance without the reflex tachycardia that alpha-1 blockers alone would cause, because the concurrent beta-1 blockade prevents the reflex. In a patient with HFrEF and angina, this combined mechanism is particularly advantageous: afterload reduction decreases the mechanical work the failing ventricle must perform (improving HF symptoms and reducing MVO₂), while the beta-blockade provides the anti-ischemic benefit. Carvedilol is one of only three beta-blockers with demonstrated mortality benefit in HFrEF (alongside metoprolol succinate from MERIT-HF and bisoprolol from CIBIS-II). The COPERNICUS trial demonstrated survival benefit in severe HFrEF, and the CAPRICORN trial demonstrated mortality reduction in post-MI patients with left ventricular dysfunction. These are the trials a prescriber is drawing on when selecting carvedilol for this dual indication. Option A: Carvedilol is non-selective, meaning it blocks both beta-1 and beta-2 receptors. It is not cardioselective. The cardioselective agents are metoprolol, bisoprolol, atenolol, and nebivolol. Carvedilol's advantage in HFrEF is its alpha-1 blocking activity and its outcomes evidence, not cardioselectivity. Option B: Carvedilol does not act as a calcium channel blocker. It is an adrenergic receptor blocker. Calcium channel antagonism is the mechanism of amlodipine, diltiazem, and verapamil, which act through an entirely different molecular target. Option C: Carvedilol does reduce heart rate through beta-1 blockade — negative chronotropy is a fundamental property shared by all beta-blockers. The clinical goal in HFrEF with carvedilol is a resting heart rate of 55–65 bpm, achieved through careful uptitration. Option D: This option inverts carvedilol's receptor profile. Carvedilol blocks beta-1 receptors in the heart (reducing heart rate and contractility) and alpha-1 receptors in the vasculature (reducing afterload). It does not selectively block beta-2 peripherally while sparing cardiac beta-1 — that profile does not describe any available beta-blocker.
11. A pharmacology instructor compares nebivolol and carvedilol, noting that both beta-blockers produce vasodilation beyond what is expected from beta-blockade alone, yet they achieve this through completely different mechanisms. Which of the following correctly describes the vasodilatory mechanism that is unique to nebivolol?
ANSWER: B
Rationale:
Nebivolol is a highly cardioselective beta-1 antagonist with an additional vasodilatory property that distinguishes it from all other beta-blockers except carvedilol — yet the mechanism is completely different. Nebivolol stimulates the production of nitric oxide (NO) from vascular endothelium by activating endothelial nitric oxide synthase (eNOS). This is mediated at least in part through agonism at beta-3 adrenergic receptors on endothelial cells, which activates eNOS and increases NO release. Nitric oxide then diffuses into adjacent vascular smooth muscle cells, activates guanylate cyclase, raises cyclic GMP, and causes smooth muscle relaxation and vasodilation. This mechanism produces peripheral vasodilation that lowers vascular resistance, reduces afterload, and explains nebivolol's more favorable effects on erectile function (NO pathway is preserved rather than impaired) and peripheral circulation compared with older beta-blockers. Carvedilol, by contrast, achieves vasodilation through direct alpha-1 adrenergic receptor blockade — a pharmacologically distinct mechanism. Understanding this distinction matters clinically: patients who cannot tolerate carvedilol's orthostatic hypotension from alpha-1 blockade may better tolerate nebivolol's NO-mediated vasodilation, which tends to be more gradual. Option A: This describes carvedilol's mechanism, not nebivolol's. Nebivolol does not block alpha-1 receptors. Attributing carvedilol's mechanism to nebivolol is a common source of confusion that this question is designed to correct. Option C: Nebivolol does not directly open potassium channels. Potassium channel opening is the mechanism of minoxidil and nicorandil, not beta-blockers. Nebivolol's vasodilation is mediated through the NO-cGMP pathway, not direct ion channel modulation. Option D: Nebivolol does not block L-type calcium channels at therapeutic doses. Calcium channel blockade is the mechanism of the DHP and non-DHP calcium channel blocker drug classes. Beta-blockers as a class, including nebivolol, act at adrenergic receptors. Option E: Nebivolol does not inhibit PDE5. PDE5 inhibition is the mechanism of sildenafil, tadalafil, and related agents. Nebivolol increases NO production at the upstream synthesis step (via eNOS); PDE5 inhibitors preserve NO's downstream signaling by preventing cGMP breakdown. These are different points in the same pathway, not the same mechanism.
12. A 55-year-old woman with type 2 diabetes and stable angina is started on bisoprolol. Her endocrinologist asks the cardiologist what counseling should be given about hypoglycemia recognition while on a beta-blocker. Which of the following most accurately describes the effect of beta-blockers on hypoglycemia awareness?
ANSWER: D
Rationale:
Hypoglycemia triggers a counter-regulatory response that includes release of epinephrine (adrenaline) from the adrenal medulla. Epinephrine stimulates multiple warning symptoms via adrenergic receptors: tachycardia and palpitations (beta-1), tremor (beta-2 in skeletal muscle), and anxiety (CNS beta effects). Beta-blockers suppress all of these adrenergically mediated symptoms. However, sweating during hypoglycemia is regulated differently: the sweat glands are innervated by sympathetic cholinergic nerve fibers, meaning the neurotransmitter at the sweat gland is acetylcholine, not norepinephrine. Since beta-blockers act at adrenergic (norepinephrine/epinephrine) receptors and have no blocking effect on muscarinic cholinergic receptors in sweat glands, sweating is fully preserved during hypoglycemia even in patients taking beta-blockers. This means a patient on bisoprolol who becomes hypoglycemic will sweat normally but will not experience the palpitations or tremor they might otherwise feel. Clinical counseling must address this: the patient should be instructed to recognize sweating as their primary early warning sign, and should monitor blood glucose more frequently during initiation of beta-blocker therapy and dose changes. Option A: Beta-blockers do not enhance hypoglycemia symptoms. They suppress the adrenergic warning signs, reducing — not increasing — the detectability of hypoglycemic episodes for symptoms that depend on adrenergic pathways. Option B: This overstates the risk. Beta-blockers do not block sweating. The statement that hypoglycemic episodes become "entirely asymptomatic" is incorrect because sweating — the most reliable early warning sign — is specifically preserved through its cholinergic pathway. Counseling should focus on this preserved symptom rather than implying total loss of warning. Option C: Hypoglycemia symptoms are substantially mediated by the adrenergic counter-regulatory response, not purely by CNS mechanisms. The adrenergic component (tachycardia, tremor, anxiety) is specifically blunted by beta-blockers; denying any adrenergic involvement is pharmacologically incorrect. Option E: There is a partial truth here — non-selective beta-blockers can modestly impair epinephrine-stimulated glycogenolysis in the liver via beta-2 receptor blockade, potentially slowing glucose recovery from hypoglycemia. However, this effect is generally modest at clinical doses, is primarily a concern with non-selective agents (propranolol, carvedilol) rather than cardioselective ones (bisoprolol), and is not the primary clinical concern addressed in routine counseling. The most important teaching point — and the most clinically actionable counseling — is the preservation of sweating as a warning sign, which is what the question asks for.
13. A patient with stable angina remains symptomatic despite metoprolol succinate 200 mg daily at a resting heart rate of 58 bpm. The cardiologist decides to add a second antianginal agent. Which of the following additions is both safe and pharmacologically rational for this patient?
ANSWER: A
Rationale:
When a patient with stable angina remains symptomatic on a maximally tolerated beta-blocker, the preferred second agent is a dihydropyridine (DHP) calcium channel blocker — most commonly amlodipine. DHP agents act selectively on vascular smooth muscle L-type calcium channels to produce peripheral vasodilation and afterload reduction, with minimal direct effect on the sinoatrial node or atrioventricular node at therapeutic doses. This vascular selectivity is critical: combining a beta-blocker with a DHP-CCB addresses three hemodynamic determinants of MVO₂ simultaneously (heart rate via the beta-blocker, contractility via the beta-blocker, afterload via amlodipine) without additive cardiac conduction depression. A common side effect of DHP agents is mild reflex tachycardia from baroreceptor activation in response to vasodilation — the concurrent beta-blocker specifically and beneficially blunts this reflex, making the combination pharmacodynamically synergistic. Metoprolol succinate ER + amlodipine is the most widely used evidence-based dual antianginal combination for stable exertional angina. Option B: Verapamil is a non-DHP calcium channel blocker that directly depresses the sinoatrial node, AV node, and myocardial contractility through the same cardiac targets as beta-blockers, via a different molecular mechanism. Adding verapamil to metoprolol is contraindicated due to the risk of severe bradycardia, high-degree AV block, and hemodynamic collapse. This is not a rational combination regardless of the symptom burden. Option C: Diltiazem is also a non-DHP calcium channel blocker and carries the same contraindication as verapamil when combined with any beta-blocker. There is no dose threshold at which the combination becomes safe. The statement that cardiac conduction effects are "neutralized at low doses" is clinically inaccurate and potentially dangerous — this is one of the most important prescribing prohibitions in antianginal pharmacology. Option D: Adding a second beta-blocker to an existing beta-blocker is not an approved or rational strategy for refractory angina. The beta-adrenergic receptor population is already maximally or near-maximally occupied; adding carvedilol provides no additional antianginal benefit and introduces new risks including bronchospasm (from beta-2 blockade) and orthostatic hypotension (from carvedilol's alpha-1 blockade). Combination beta-blocker therapy is not used in clinical practice for this indication. Option E: Ranolazine inhibits the late sodium current (late INa) in cardiac myocytes — a mechanism entirely distinct from beta-adrenergic receptor blockade. It has no meaningful effect on sinoatrial node automaticity and does not worsen bradycardia or AV conduction. Ranolazine is specifically recommended as an add-on agent for refractory angina in patients already on a beta-blocker precisely because it has no hemodynamic interaction. The premise of this option is pharmacologically incorrect.
14. A 42-year-old woman with episodic hypertension, palpitations, and diaphoresis is found to have a pheochromocytoma (a tumor of the adrenal medulla that secretes large amounts of epinephrine and norepinephrine into the bloodstream). She also has exertional chest pain, and a cardiologist considers starting a beta-blocker for suspected angina. Why is starting a beta-blocker without first establishing alpha-blockade dangerous in this patient?
ANSWER: C
Rationale:
Pheochromocytoma releases large quantities of catecholamines — primarily epinephrine and norepinephrine — that act simultaneously on alpha-1 and beta-2 receptors in vascular smooth muscle. Alpha-1 receptor activation produces vasoconstriction, while beta-2 receptor activation produces vasodilation. In a patient with an active pheochromocytoma, these two opposing influences are present simultaneously, and blood pressure is the net result of their balance. When a beta-blocker is administered first, beta-2-mediated vasodilation is removed from this balance. Alpha-1-mediated vasoconstriction now operates without its counterweight, producing a dramatic and potentially catastrophic rise in blood pressure — a hypertensive emergency. The correct management sequence is to establish alpha-blockade first (typically with phenoxybenzamine, a non-selective irreversible alpha-blocker, or doxazosin, for one to two weeks preoperatively), which blocks the alpha-1-mediated vasoconstriction. Only after adequate alpha-blockade is established is it safe to add a beta-blocker to control the reflex tachycardia that alpha-blockade itself produces. Reversing this sequence — beta before alpha — is one of the most dangerous prescribing errors in the perioperative management of pheochromocytoma. Option A: Beta-blockers do not stimulate catecholamine release from pheochromocytoma cells. Presynaptic beta-2 receptor autofeedback is a normal neural phenomenon but does not apply to tumor catecholamine secretion in this way. The danger in pheochromocytoma is a vascular receptor imbalance, not increased tumor secretion. Option B: The danger in pheochromocytoma is uncontrolled hypertension from unopposed alpha-1 vasoconstriction — not cardiac decompensation from loss of protective tachycardia. Beta-blockade in this context lowers heart rate as expected; the life-threatening risk is the blood pressure crisis in the peripheral vasculature, not a cardiac rhythm emergency. Option D: Catecholamines do not inhibit hepatic drug metabolism. Drug metabolism by CYP enzymes is not regulated by circulating catecholamine levels in a clinically meaningful way. This mechanism does not explain the danger of beta-blockers in pheochromocytoma. Option E: Beta-blockers have no agonist activity at dopamine receptors and do not stimulate catecholamine synthesis in the adrenal medulla or in pheochromocytoma cells. This option describes a pharmacological mechanism that does not exist.
15. A 48-year-old man with stable angina has been on propranolol for several years and reports troublesome vivid nightmares, significant fatigue, and difficulty sleeping. His physician considers switching him to atenolol. Which property of propranolol best explains these central nervous system adverse effects, and why would atenolol be expected to cause fewer of them?
ANSWER: E
Rationale:
The blood-brain barrier is a selective permeability barrier that allows lipid-soluble (lipophilic) molecules to cross readily while restricting water-soluble (hydrophilic) molecules. Propranolol is highly lipophilic — it dissolves readily in fat — and crosses the blood-brain barrier with ease, achieving significant CNS concentrations. Once in the CNS, propranolol blocks beta-adrenergic receptors in brain regions that regulate sleep, mood, and autonomic tone, producing vivid dreams and nightmares, sleep disturbance and insomnia, fatigue and lethargy, and in some patients, depressive symptoms. These are well-documented adverse effects of propranolol and other lipophilic beta-blockers such as metoprolol. Atenolol, by contrast, is highly hydrophilic — it does not dissolve in fat readily and crosses the blood-brain barrier minimally, keeping CNS concentrations very low at therapeutic doses. A patient switched from propranolol to atenolol typically experiences the same degree of cardiac beta-1 blockade (heart rate and blood pressure control) with a substantially reduced burden of CNS side effects. This pharmacokinetic difference — lipophilicity driving CNS penetration — is one of the most clinically useful principles for selecting among beta-blockers when tolerability is the primary concern. Option A: Cardioselectivity refers to the relative affinity for beta-1 versus beta-2 receptors, not to CNS penetration. Atenolol's lower CNS side effect burden is due to its hydrophilicity, not its cardioselectivity. A cardioselective but lipophilic agent (such as metoprolol) causes significant CNS effects. The two properties are pharmacologically independent. Option B: Propranolol is not renally eliminated — it undergoes extensive hepatic first-pass metabolism with oral bioavailability of approximately 30%. Renal elimination is a property of atenolol, not propranolol. This option reverses the elimination routes of the two drugs. Option C: Propranolol has no meaningful monoamine oxidase inhibitory activity at therapeutic doses. MAO inhibition is the mechanism of a completely different drug class (MAOIs such as phenelzine and tranylcypromine) used in psychiatry. Attributing this mechanism to propranolol is pharmacologically incorrect. Option D: Propranolol has a half-life of approximately 3–6 hours, not 48–72 hours. Atenolol's half-life is 6–9 hours — actually longer than propranolol's. The CNS side effect difference is not explained by half-life and would not be explained even if the half-lives were as stated in the option, since CNS penetration depends on lipophilicity, not duration of exposure per se.
16. A 61-year-old man with a myocardial infarction (MI — a heart attack, in which a coronary artery is blocked and heart muscle dies from lack of oxygen) six weeks ago is being discharged from a cardiac rehabilitation program. He has residual exertional angina. His cardiologist emphasizes the importance of continuing metoprolol succinate indefinitely. Which of the following best describes the benefits of beta-blocker therapy in the post-MI patient with ongoing angina?
ANSWER: B
Rationale:
Beta-blockers provide multiple distinct and additive benefits in the post-MI patient that extend far beyond simple angina control. First, they reduce sympathetic tone on the myocardium, raising the threshold for ventricular fibrillation (the most common mechanism of sudden cardiac death post-MI) — this anti-arrhythmic effect is mediated through beta-1 receptor blockade on Purkinje fibers and ventricular myocytes. Second, by reducing heart rate and contractility, they lower wall stress during the healing phase of the infarcted zone, attenuating the adverse remodeling process (chamber dilation, shape distortion, and progressive dysfunction) that would otherwise occur. Third, they reduce the risk of reinfarction, likely through hemodynamic stabilization, reduced coronary plaque rupture risk from lower shear forces, and anti-arrhythmic protection. Fourth, they continue to provide antianginal benefit in patients with residual ischemic symptoms by reducing MVO₂. The combination of these mechanisms explains why beta-blockers are a Class I recommendation in post-MI management regardless of ejection fraction when angina is present. The REDUCE-AMI trial (2024) raised questions about indefinite beta-blocker use specifically in post-MI patients with preserved ejection fraction and no angina; however, when angina is present — as in this patient — continuation is clearly indicated. Option A: Beta-blockers continue to reduce heart rate post-MI through the intact sinoatrial node — sinus node damage is uncommon and does not eliminate the drug's chronotropic benefit in most patients. The claim that antianginal mechanism does not apply post-MI is incorrect; heart rate reduction and MVO₂ reduction are as relevant after MI as before it. Option C: While beta-blockers do have modest anti-arrhythmic effects relevant to atrial fibrillation, the primary mortality benefit post-MI is reduction of sudden cardiac death via ventricular arrhythmia suppression and anti-remodeling effects. Atrial fibrillation prevention is not the principal indication or primary established benefit driving post-MI recommendations. Option D: Beta-blockers have no direct antiplatelet effect and do not prevent coronary restenosis. Restenosis prevention is the domain of dual antiplatelet therapy (aspirin plus P2Y12 inhibitor) and stent technology. Attributing an antirestenosis mechanism to beta-blockers is pharmacologically incorrect. Option E: While the REDUCE-AMI trial (2024) raises questions about indefinite beta-blocker use in post-MI patients with preserved EF and no symptoms, this patient has residual angina, which clearly justifies continuation. The statement that beta-blockers provide no mortality benefit in preserved-EF patients is an oversimplification of an evolving evidence base; and in the presence of angina, the indication is unambiguous regardless of EF.
17. A 70-year-old man with stable angina also has moderate COPD (chronic obstructive pulmonary disease — a lung condition characterized by airflow limitation; patients may have airway inflammation and some degree of bronchospasm). He has no history of asthma and spirometry shows fixed airflow obstruction without significant reversibility after bronchodilator. His pulmonologist asks whether a beta-blocker is safe for his angina. Which of the following most accurately describes the appropriate approach?
ANSWER: D
Rationale:
The management of beta-blocker use in COPD requires understanding both the pharmacology of cardioselectivity and the real-world evidence base. Cardioselective beta-blockers such as bisoprolol, metoprolol, and atenolol have a preferential affinity for beta-1 receptors over beta-2 receptors. Beta-2 receptors in bronchial smooth muscle mediate bronchodilation; when these are blocked, bronchospasm can result. However, in patients with COPD who have fixed airflow obstruction without significant reversibility, the airway smooth muscle is less responsive to beta-2 receptor-mediated bronchodilation to begin with — meaning that modest beta-2 blockade produces correspondingly less functional impairment. Multiple studies and the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for COPD management specifically note that cardioselective beta-blockers are not contraindicated in COPD and are underused in this population despite clear cardiovascular benefit. Bisoprolol is the preferred agent given its highest beta-1/beta-2 selectivity ratio. The clinical principle is proportionality: the cardiovascular mortality benefit of beta-blocker therapy post-MI and in angina is large and well-established; the bronchospasm risk with cardioselective agents in fixed-obstruction COPD is modest and manageable. Active asthma with significant reversibility, however, is a different situation — beta-blockers should be avoided or used with extreme caution in that setting because the reversible component means significant beta-2-sensitive bronchospasm risk remains. Option A: This overstates the contraindication. Absolute contraindication applies to active bronchospastic asthma, not to all COPD regardless of reversibility. The statement that "even a single dose can precipitate fatal bronchospasm" does not accurately characterize the risk profile of cardioselective agents in fixed-obstruction COPD, and applying this blanket prohibition denies patients a class of drugs with proven mortality benefit after MI. Option B: There is no evidence that long-acting bronchodilators must be co-administered to make beta-blockers safe in COPD, nor do bronchodilators "fully offset" any potential bronchospastic risk in a mechanistic sense. Cardioselective agents can be used on their own in appropriately selected COPD patients. Option C: Non-selective beta-blockers are not preferred in COPD — quite the opposite. Blocking beta-2 receptors in airways with a non-selective agent (propranolol, carvedilol) increases bronchospasm risk substantially compared with cardioselective agents. There is no mechanism by which beta-2 blockade reduces airway inflammation via mast cell degranulation inhibition in the manner described; this option presents a fabricated mechanism. Option E: There are no inhaled systemic beta-blockers for angina in clinical use. Beta-blockers for angina are administered orally or intravenously. The pharmacokinetic principle described — restriction of systemic distribution by inhalation — does not apply to this drug class in this context.
18. A pharmacist is counseling a patient newly started on carvedilol for angina and heart failure. The patient asks whether it matters whether he takes the tablet with or without food. Which of the following best describes the correct counseling and the pharmacokinetic rationale for it?
ANSWER: A
Rationale:
Carvedilol is a lipophilic drug with significant first-pass hepatic metabolism producing an oral bioavailability of approximately 25–35%. Food intake slows gastric emptying and the rate at which carvedilol enters the small intestine and is absorbed, thereby reducing the rate of absorption (slower Tmax) and attenuating the peak plasma concentration (lower Cmax) without meaningfully reducing the total amount absorbed (bioavailability is preserved or marginally increased with food, not reduced). The clinical importance of this pharmacokinetic interaction lies in carvedilol's alpha-1 adrenergic receptor blocking activity: peak plasma concentrations produce the most pronounced alpha-1 blockade and the greatest risk of orthostatic hypotension, which can be severe enough to cause falls, particularly after the first dose or an initial dose increase. By taking carvedilol with food, the peak is blunted, reducing this risk. This is why the prescribing information for carvedilol specifically instructs patients to take it with food, and why pharmacist counseling on this point is clinically meaningful rather than merely administrative. Option B: Food does not induce intestinal CYP3A4 enzymes in a clinically meaningful way, and carvedilol is not primarily metabolized by CYP3A4 — it uses CYP2D6 and CYP2C9. The premise of this option is pharmacologically incorrect, and the recommended action (empty stomach) is the opposite of what should be advised. Option C: Carvedilol is highly lipophilic — this is the opposite of hydrophilic. Food does affect its absorption kinetics, specifically by slowing the rate of absorption. The option's pharmacological characterization of carvedilol is incorrect. Option D: The risk of orthostatic hypotension from carvedilol's alpha-1 blocking activity is not dose-threshold limited in the way this option implies. Alpha-1 blockade occurs at all therapeutic doses of carvedilol, and peak-concentration effects on blood pressure are relevant regardless of whether the dose is at the lower or upper end of the therapeutic range. Taking carvedilol with food is recommended across the full dose range. Option E: Carvedilol is not a prodrug — it does not require first-pass hepatic metabolism to convert to an active form. It is pharmacologically active as administered. First-pass metabolism actually reduces (not increases) systemic bioavailability; food does not specifically inhibit first-pass extraction in a therapeutically relevant way. The entire mechanism described in this option is pharmacologically invented.
19. A 72-year-old woman with known heart failure with reduced ejection fraction (HFrEF) and angina is admitted to the hospital in acute decompensated heart failure (ADHF — a condition in which heart failure acutely worsens, producing fluid overload, pulmonary congestion, and reduced cardiac output). She is currently volume-overloaded with orthopnea and bilateral crackles. A medical student suggests starting carvedilol immediately to improve her long-term prognosis. Why is this approach incorrect?
ANSWER: C
Rationale:
Beta-blockers have proven mortality benefit in chronic stable HFrEF, but this benefit depends critically on the hemodynamic state at the time of initiation. The negative inotropic effect (reduction in myocardial contractility) and negative chronotropic effect (reduction in heart rate) of beta-blockers that are beneficial in the long-term compensated state become dangerous in the setting of acute decompensation. A patient in ADHF is already struggling to maintain adequate cardiac output; the heart is dependent on elevated sympathetic drive — and the resulting elevated heart rate and contractility — to maintain perfusion pressure. Blocking this compensatory sympathetic activation acutely reduces an already-inadequate cardiac output, worsening hypoperfusion, pulmonary edema, and potentially precipitating cardiogenic shock. The correct approach is to stabilize the patient first: achieve euvolemia with intravenous diuretics, optimize volume status, restore hemodynamic stability, and then — once the patient is comfortable, dry, and not requiring intravenous inotropic support — initiate beta-blocker at the lowest available dose with careful uptitration over weeks. If a patient on chronic beta-blocker therapy is admitted with ADHF, the beta-blocker is typically continued at a reduced dose or held temporarily rather than abruptly stopped, to avoid withdrawal syndrome. Option A: Carvedilol is approved and guideline-recommended specifically for HFrEF — it is one of the three beta-blockers with Class I evidence for mortality benefit in reduced-EF heart failure. The claim that it is contraindicated in HFrEF is the exact opposite of the evidence base. Option B: Carvedilol's alpha-1 blocking activity produces vasodilation and afterload reduction, not diuresis. Alpha-1 blockade reduces vascular resistance; it has no direct effect on renal tubular sodium handling or urinary output. The mechanism of diuresis in heart failure management is loop diuretics (furosemide, bumetanide), not adrenergic blockers. Option D: While there is a partial truth in that beta-blockers do blunt compensatory adrenergic activation, framing this as an absolute contraindication because sympathetic activation is "the only mechanism keeping the patient alive" overstates the case and is not the clinical teaching point. The contraindication is specifically about timing — acute decompensation — not a permanent prohibition. Once the patient is stabilized, beta-blocker initiation is mandatory for mortality benefit in HFrEF. Option E: Volume of distribution does change in fluid overload states, and this can affect pharmacokinetics of some drugs. However, this is not the primary reason or the guideline-stated rationale for deferring beta-blocker initiation in ADHF. The reason is hemodynamic: negative inotropy in a hemodynamically compromised patient is the direct clinical danger.
20. A 66-year-old man with stable angina continues to have two to three anginal episodes per week despite metoprolol succinate 200 mg daily (resting HR 57 bpm) and amlodipine 10 mg daily. He has no heart failure, no QT prolongation on ECG, and no significant renal impairment. The cardiologist considers adding a third antianginal agent. Which of the following is the most appropriate add-on therapy and why?
ANSWER: E
Rationale:
When a patient with stable angina remains symptomatic on maximally tolerated beta-blocker and DHP-CCB — the standard first-line dual combination — the next pharmacological step is an agent that addresses a different mechanism without compounding the hemodynamic effects already achieved. Ranolazine is specifically designed for this role. It inhibits the late sodium current (late INa) in cardiac myocytes — a pathological inward sodium current that develops in ischemic cells and leads to sodium accumulation, secondary calcium overload via the sodium-calcium exchanger, and worsening diastolic dysfunction and contractile impairment. By blocking this current, ranolazine reduces ischemia-driven myocyte dysfunction without altering heart rate, blood pressure, or AV conduction. This hemodynamic neutrality is its key clinical advantage in refractory angina: the patient's heart rate is already at target (57 bpm), and further reduction is not possible or safe. Ranolazine can be added to any combination of antianginal agents without concern for additive bradycardia, hypotension, or AV block. It is specifically recommended in ESC and ACC/AHA guidelines as add-on therapy for refractory angina. Option A: Switching from metoprolol to bisoprolol within the same drug class provides no additional antianginal benefit — the mechanism is identical (beta-1 blockade) and the heart rate target is already achieved. The question asks for a third agent, not a within-class substitution. Option B: Adding verapamil to metoprolol is contraindicated, as established in earlier questions in this set. Both drugs depress the SA node, AV node, and myocardial contractility; their combined use risks severe bradycardia, heart block, and hemodynamic collapse. This is one of the most important prohibitions in antianginal prescribing. Option C: Ivabradine is a selective If channel inhibitor that reduces heart rate in sinus rhythm patients. It is a valid add-on for angina when resting heart rate remains above 70 bpm despite beta-blocker therapy. However, this patient's resting heart rate is already 57 bpm — ivabradine is not appropriate because further heart rate reduction would be dangerous (excessive bradycardia). The guideline threshold for ivabradine use as add-on to beta-blocker therapy requires resting HR above 60–70 bpm. Option D: A long-acting nitrate is a reasonable third-line option for refractory angina and is not incorrect in principle. However, the question specifically presents a patient with no contraindications to ranolazine and describes a clinical picture (HR at target, hemodynamics already optimized) that makes ranolazine the most pharmacologically elegant and guideline-supported answer. Nitrates also require careful management of nitrate-free intervals to prevent tolerance, adding a compliance complexity. Ranolazine is the intended answer in this clinical context.
21. A cardiologist is reviewing the medication interactions for patients on beta-blockers who also require psychiatric medications. Which of the following psychiatric drugs poses the most significant pharmacokinetic interaction risk with metoprolol, nebivolol, and carvedilol — and which beta-blocker would avoid this risk entirely?
ANSWER: B
Rationale:
Metoprolol, nebivolol, and carvedilol are all substantially metabolized by CYP2D6 (cytochrome P450 2D6), making them vulnerable to pharmacokinetic interactions with any drug that inhibits this enzyme. Fluoxetine, paroxetine, and bupropion are among the most potent CYP2D6 inhibitors in common clinical use, all prescribed for depression, anxiety, or smoking cessation — conditions frequently comorbid with cardiovascular disease. When any of these agents is added to a stable regimen of metoprolol, nebivolol, or carvedilol, CYP2D6 is inhibited, the beta-blocker's primary elimination pathway is blocked, and plasma concentrations rise substantially — in some cases to two to five times their previous level depending on the extent of inhibition and the patient's baseline metabolizer status. The clinical result is excessive beta-1 blockade: symptomatic bradycardia, hypotension, fatigue, and exercise intolerance. Bisoprolol is metabolized by CYP3A4, not CYP2D6; inhibiting CYP2D6 has no effect on bisoprolol clearance whatsoever. When a patient on one of these psychiatric medications requires a beta-blocker, bisoprolol is the rational selection precisely because it bypasses the CYP2D6 interaction entirely. Option A: Metoprolol is not eliminated by renal tubular secretion — it is primarily hepatically metabolized via CYP2D6. Lithium does not inhibit CYP2D6 and has no meaningful pharmacokinetic interaction with metoprolol through the mechanism described. The tubular secretion competition mechanism is relevant to some drugs (e.g., metformin with cimetidine) but does not apply here. Option C: Quetiapine is an atypical antipsychotic that works at dopamine and serotonin receptors; it does not directly stimulate beta-1 adrenergic receptors and does not produce additive chronotropic effects in the manner described. This option describes a mechanism that does not exist for quetiapine. Option D: Sertraline is a mild CYP2D6 inhibitor and a more moderate CYP3A4 inhibitor. It does not inhibit CYP3A4 potently enough to produce the degree of clinical interaction described, and it is not the agent posing the highest interaction risk with the named beta-blockers. Bisoprolol's CYP3A4 metabolism does not create the same vulnerability as the CYP2D6-metabolized agents because sertraline's CYP3A4 inhibition is not potent enough to produce clinically significant bisoprolol accumulation in practice. Option E: Benzodiazepines do not produce a pharmacokinetic interaction with beta-blockers. They act at GABA-A receptors in the CNS; while lipophilic beta-blockers do cause CNS effects (fatigue, sedation), this is not a receptor-level synergism with benzodiazepines at the brainstem in the manner described, and respiratory depression is not a recognized risk of combining beta-blockers with benzodiazepines at therapeutic doses.
22. A patient with stable angina is being uptitrated on metoprolol succinate every two weeks. The cardiologist explains that they are targeting a specific resting heart rate as a guide to optimal dosing. Which of the following best describes the resting heart rate target and the clinical rationale for it?
ANSWER: D
Rationale:
Beta-blocker dosing in stable angina is guided by a resting heart rate target of approximately 55–60 bpm, with titration occurring every two weeks as tolerated. This target reflects the pharmacodynamic goal: sufficient beta-1 receptor occupancy to reduce myocardial oxygen demand (MVO₂) consistently across the entire day, not merely at rest. Heart rate is the single most controllable determinant of MVO₂, and because the heart beats continuously — including during sleep, at meals, and during the minimal exertion of daily life — even resting heart rate reduction translates into meaningful cumulative oxygen demand reduction over 24 hours. A resting rate of 55–60 bpm typically indicates adequate blockade for antianginal purposes. Rates below 50 bpm are associated with symptomatic bradycardia, dizziness, fatigue, and impaired exercise capacity that diminish quality of life and medication adherence. Rates above 70 bpm suggest under-dosing for antianginal intent. Dose increases are made every two weeks because metoprolol succinate reaches steady state within several days but the full hemodynamic adaptation (including any reflex changes) requires a longer interval to assess accurately. This titration interval also allows safe detection of adverse effects before proceeding to the next dose increment. Option A: A target of 40–45 bpm is excessively low. At these rates, cardiac output is significantly reduced, and patients routinely experience symptomatic bradycardia, fatigue, dizziness, and impaired functional capacity. This degree of heart rate reduction is not the clinical target for angina management and is associated with harm rather than benefit. Option B: A resting target of 70–80 bpm represents under-treatment for most patients with stable angina on beta-blocker therapy. This range does not indicate meaningful beta-1 receptor blockade in a patient who likely had a resting heart rate of 75–85 bpm at baseline and whose MVO₂ at rest remains near the pre-treatment level. Maintaining exercise tolerance is important, but it is achieved within the 55–60 bpm target range — not by aiming for near-normal heart rates. Option C: Beta-blocker titration in angina does use heart rate as a guide; it is not titrated purely to maximal tolerated dose. Heart rate is a readily measurable pharmacodynamic endpoint that correlates with beta-1 blockade and antianginal efficacy, and it is the standard clinical titration target referenced in ESC and ACC/AHA guidelines. Option E: A target below 50 bpm is not recommended in clinical guidelines and would produce unacceptable rates of symptomatic bradycardia, exercise limitation, and adverse effects. The evidence base for antianginal efficacy does not support targeting heart rates below 55 bpm as the standard goal.